Quantitative characterization of intact sialylated O-glycans with MALDI-MS for protein biotherapeutics

For validating O-glycosylation of protein biotherapeutics, we presented a quantitative O-glycomics method which is based on the neutralization of sialic acids, the specific release of O-glycans, and the introduction of permanent positive charge followed by quantitative MALDI-MS analysis. This method...

Full description

Saved in:
Bibliographic Details
Published in:The Korean journal of chemical engineering 2018, 35(7), 220, pp.1462-1467
Main Authors: Hwang, Cheol-Hwan, Park, Hae-Min, Park, Han-Gyu, Ahn, Da-Hee, Kim, Seong-Min, Ko, Byoung Joon, Kim, Young Hwan, Yang, Yung-Hun, Kim, Yun-Gon
Format: Article
Language:English
Subjects:
Biotechnology
Catalysis
Chemistry
Chemistry and Materials Science
Industrial Chemistry/Chemical Engineering
Linearity
Materials Science
Proteins
Quantitative analysis
Reproducibility
Sensitivity analysis
화학공학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For validating O-glycosylation of protein biotherapeutics, we presented a quantitative O-glycomics method which is based on the neutralization of sialic acids, the specific release of O-glycans, and the introduction of permanent positive charge followed by quantitative MALDI-MS analysis. This method shows excellent technical reproducibility, linearity and sensitivity. In addition, it enables the quantification of intact O-glycans with minimal degradation or loss of sialic acids on these glycans compared to a conventional HPLC-based method. We then applied this method to quantitatively characterize O-glycans present on Etanercept. The analysis showed the relative abundances of mono- and di-sialylated core 1 O-glycans - were 79.3±0.8% and 17.3±1.4%, respectively. This glycomics technology could allow for the reliable quantitative analysis of intact O-glycans from glycoproteins and may contribute to validation of O-glycosylation protein biotherapeutics in the pharmaceutical industry.
ISSN:0256-1115
1975-7220
DOI:10.1007/s11814-018-0058-0